Nature Medicine, Published online: 21 July 2026; doi:10.1038/s41591-026-04527-y
In two patients with SCN2A epileptic encephalopathy, treatment with personalized allele-selective antisense oligonucleotides led to a decrease in seizure frequency with a positive safety profile.
